Thursday, February 7, 2013

• Galectin Therapeutics Executive Chairman, James Czirr to Appear on “The RedChip Money Report” on FOX Business NewsBusiness Wire (Thu, Feb 7)
• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online (Thu, Feb 7)

Tuesday, February 5, 2013

• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online (Tue, Feb 5)

Friday, February 1, 2013

• 2 Small-Cap Biotech Companies With Zero Debt And At Least $10 Million In Cashat Seeking Alpha (Fri, Feb 1)

Thursday, January 31, 2013

• 4 Healthcare Stock Stories for Almost-The-Weekend Readingat Wall St. Cheat Sheet (Thu, Jan 31)
• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online (Thu, Jan 31)
• Galectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver DiseaseBusiness Wire (Thu, Jan 31)

Monday, January 28, 2013

• Galectin Therapeutics Inc. Announces Publication of Galectin Symposium Proceedings by the American Chemical SocietyBusiness Wire (Mon, Jan 28)

Tuesday, January 22, 2013

• New Potential Therapy for Diabetic Kidney Disease: Galectin Therapeutics Announces Anti-Galectin Drug is Effective in Preclinical StudiesBusiness Wire (Tue, Jan 22)

Tuesday, January 15, 2013

• Galectin Therapeutics Appoints Industry Veteran Rex Horton as Executive Director of Regulatory Affairs and Quality AssuranceBusiness Wire (Tue, Jan 15)

Tuesday, November 27, 2012

• Biotech Industry Skyrockets in 2012 as FDA New Drug Approval Rate IncreasesMarketwired (Tue, Nov 27)

Monday, November 26, 2012

• Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and CirrhosisBusiness Wire (Mon, Nov 26)

Tuesday, November 13, 2012

• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online (Tue, Nov 13)

Monday, November 12, 2012

• Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012Business Wire (Mon, Nov 12)

Friday, November 9, 2012

• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online (Fri, Nov 9)
• Galectin Therapeutics Reports Third Quarter 2012 Financial ResultsBusiness Wire (Fri, Nov 9)
• GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online (Fri, Nov 9)

Wednesday, October 17, 2012

• 4 Biotechs Targeting Fibrosisat Seeking Alpha (Wed, Oct 17)

Monday, October 15, 2012

• 5 Healthcare Companies With Insider Buying During October 2012at Seeking Alpha (Mon, Oct 15)

Thursday, October 4, 2012

• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Termination of a Material Definitive AgreementEDGAR Online (Thu, Oct 4)

Friday, September 21, 2012

• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhEDGAR Online (Fri, Sep 21)

Thursday, August 30, 2012

• Healthcare Business Recap: Genetic Tech POPS, Dendreon PERSEVERESat Wall St. Cheat Sheet (Thu, Aug 30)

Wednesday, August 29, 2012

• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhEDGAR Online (Wed, Aug 29)

Friday, August 10, 2012

• GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online (Fri, Aug 10)
• GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online (Fri, Aug 10)

Add GALT News to My Yahoo!